Qiagen Gets U.S. Clearance for Gastrointestinal-Illness Test

Dow Jones

01-10

By Dean Seal

Qiagen has received clearance from U.S. regulators to market its gastrointestinal-illness test.

The Netherlands life-sciences and diagnostics company said Thursday that the Food and Drug Administration's clearance involves the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, which covers five causes of gastrointestinal illness that are recommended by the Infectious Diseases Society of America.

Among the illnesses are salmonella and norovirus, which is one of the most common causes of gastrointestinal infection and an important virus to target during the winter season.

The company plans to submit a second version of the panel, which will cover five common bacterial pathogens, to the FDA in the coming weeks.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

January 09, 2025 17:09 ET (22:09 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2502020748"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502020748\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2502020748?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-10 06:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502020748","market":"hk","top_or_hot":-1,"title":"Qiagen Gets U.S. Clearance for Gastrointestinal-Illness Test","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Qiagen has received clearance from U.S. regulators to market its gastrointestinal-illness test. \n</p>\n<p>\n  The Netherlands life-sciences and diagnostics company said Thursday that the Food and Drug Administration's clearance involves the QIAstat-Dx Gastrointestinal Panel 2 Mini B&amp;V, which covers five causes of gastrointestinal illness that are recommended by the Infectious Diseases Society of America. \n</p>\n<p>\n  Among the illnesses are salmonella and norovirus, which is one of the most common causes of gastrointestinal infection and an important virus to target during the winter season. \n</p>\n<p>\n  The company plans to submit a second version of the panel, which will cover five common bacterial pathogens, to the FDA in the coming weeks. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 09, 2025 17:09 ET (22:09 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qiagen Gets U.S. Clearance for Gastrointestinal-Illness Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQiagen Gets U.S. Clearance for Gastrointestinal-Illness Test\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-01-10 06:09</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Qiagen has received clearance from U.S. regulators to market its gastrointestinal-illness test. \n</p>\n<p>\n  The Netherlands life-sciences and diagnostics company said Thursday that the Food and Drug Administration's clearance involves the QIAstat-Dx Gastrointestinal Panel 2 Mini B&amp;V, which covers five causes of gastrointestinal illness that are recommended by the Infectious Diseases Society of America. \n</p>\n<p>\n  Among the illnesses are salmonella and norovirus, which is one of the most common causes of gastrointestinal infection and an important virus to target during the winter season. \n</p>\n<p>\n  The company plans to submit a second version of the panel, which will cover five common bacterial pathogens, to the FDA in the coming weeks. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 09, 2025 17:09 ET (22:09 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2125909247.SGD","symbol_name":"Natixis Thematics Meta H-R/A SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2502020748","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502020748","pubTimestamp":1736460540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Qiagen has received clearance from U.S. regulators to market its gastrointestinal-illness test.The Netherlands life-sciences and diagnostics company said Thursday that the Food and Drug Administration's clearance involves the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, which covers five causes of gastrointestinal illness that are recommended by the Infectious Diseases Society of America.Among the illnesses are salmonella and norovirus, which is one of the most common causes of gastrointestinal infection and an important virus to target during the winter season.The company plans to submit a second version of the panel, which will cover five common bacterial pathogens, to the FDA in the coming weeks.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","BK4121":"生命科学工具和服务","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU1923622614.USD":"Natixis Thematics Meta R/A USD","QGEN":"快而精医药"},"translate_title":"Qiagen获得美国胃肠道疾病测试许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QGEN":0.9},"content_text":"By Dean Seal \n\n\n \n\n\n  Qiagen has received clearance from U.S. regulators to market its gastrointestinal-illness test. \n\n\n  The Netherlands life-sciences and diagnostics company said Thursday that the Food and Drug Administration's clearance involves the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, which covers five causes of gastrointestinal illness that are recommended by the Infectious Diseases Society of America. \n\n\n  Among the illnesses are salmonella and norovirus, which is one of the most common causes of gastrointestinal infection and an important virus to target during the winter season. \n\n\n  The company plans to submit a second version of the panel, which will cover five common bacterial pathogens, to the FDA in the coming weeks. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2025 17:09 ET (22:09 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}